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Radiolabeled nano-peptides show specificity for an
animal model of human PC3 prostate cancer cells
Bluma Linkowski Faintuch, Gustavo Eutimio Ferna ´ndez Nu ´n ˜ez, Rodrigo Teodoro, Ana M. Moro,
Jair Mengatti
Instituto de Pesquisas Energe ´ticas e Nucleares - Centro de Radiofarma ´cia, Sa ˜o Paulo, Brazil.
OBJECTIVES: Cancer has been investigated using various pre-targeting techniques or models focusing on
radiobombesin analogues; however, both are not offered together. In this study, nano-bombesin labeling by a
pre-targeting system was undertaken to develop an alternative approach for prostate tumor treatment.
METHODS: A two-step pre-targeting system utilizing a combination of streptavidin (SA), biotinylated morpholino
(B-MORF), biotinylated BBN (B-BBN) with two different spacers (b-Ala and PEG), and a radiolabeled cMORF was
evaluated in vitro and in vivo.
RESULTS: Final conjugation conditions consisted of a 1:1:2 ratio of SA:B-MORF:B-BBN, followed by addition of
99mTc-cMORF to compensate for free MORF. In vitro binding experiments with prostate cancer cells (PC-3) revealed
that total binding was time-dependent for the Ala spacer but not for the PEG spacer. The highest accumulation
(5.06¡1.98 %) was achieved with 1 hour of incubation, decreasing as time progressed. Specific binding fell to
1.05¡0.35 %. The pre-targeting biodistribution in healthy Swiss mice was measured at different time points, with
the best responses observed for 7-h and 15-h incubations. The effector,
99mTc-MAG3-cMORF, was administered 2 h
later. Strong kidney excretion was always documented. The greatest tumor uptake was 2.58¡0.59 %ID/g at 7 h for
B-bAla-BBN, with a region of interest (ROI) value of 3.9 % during imaging. The tumor/blood ratio was low due to
the slow blood clearance; however, the tumor/muscle ratio was 5.95.
CONCLUSIONS: The pre-targeting approach with a peptide was a viable concept. Further evaluation with modified
sequences of MORF, including less cytosine, and additional test intervals could be worthwhile.
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INTRODUCTION
Prostate cancer is the most common non-skin malignancy
in men, leading to substantial morbidity and mortality.
Rectal examination, prostate specific antigen (PSA) and
imaging methods such as computed tomography, magnetic
resonance imaging and transrectal ultrasound are all useful
for diagnosis and staging of this disease. Yet, all of them
suffer from accuracy limitations in early cancer, especially
concerning differentiation between clinically insignificant
lesions that should better be left alone, and those that
deserve radical treatment.
1 Functional and molecular radio-
pharmaceutical imaging offers the possibility of disclosing
cellular processes, potentially representing an advance in
the identification of invasive and metastasizing lesions.
2
Nanoparticles or nanocarriers exhibit advantageous
pharmacokinetics and bioavailability in the context of
cancer diagnosis and therapy.
3
Receptor-binding radiotracers for tumor diagnosis have
been extensively studied including bombesin, a neuropep-
tide with affinity for prostate as well as breast tumors.
4
Since Anastasi et al.
5 bombesin (BBN), originally isolated
from amphibian skin, has been mostly collected from
porcine gastric tissue which expresses gastrin-releasing
peptide (GRP), a similar molecule with potent gastrin
releasing action.
6
Bombesin has a structure closely related to that of several
mammalian peptides, including the alluded to GRP, also
known as BB2, neuromedin B (BB1), and additional BB3 and
BB4 subtypes. Physiological effects are triggered by binding
to specific cell receptors, including growth of some
categories of tumor cells.
7
BBN analogues have been radiolabeled with multiple
radioisotopes and techniques, more recently focusing
nanoparticles.
3 Analogues like the truncated BBN[7-
14]NH2 sequence have been labeled with
99mTc,
111In,
90Y,
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32764Cu,
8 177Lu,
18Fo r
68Ga.
4 This fragment is convenient as a
highly specific GRP-receptor–binding motif.
9,10 Neverthe-
less, publications addressing the pretargeting system have
not been identified in the literature.
Morpholinos (MORFs) are oligomers in which a phos-
phorodiamidate backbone replaces the sugar phosphodie-
ster linkage in natural DNAs and RNAs. They resist
degradative nucleases and are endowed with high efficacy
and specificity of hybridization.
11
Pretargeting agents are usually antitumor antibodies,
12
whereas peptides have received very limited attention thus
far. Carrier molecules are often employed to increase
cellular uptake in connection with antisense tumoral targets,
and also in other applications that require oligomers and
transmembrane migration.
13
The preparation of oligomers with a carrier by covalent
conjugation is difficult. This trouble can be avoided by
utilization of streptavidin, a convenient linker for biotiny-
lated carriers and oligomers because it requires only simple
mixing.
14
Investigations in cancer dealing with various pretargeting
techniques, as well as models focusing radiobombesin
analogues are available, but not both together.
By means of
99mTc, bombesin has been radiolabeled using
tetradentate N3S, P2S2,N 4 chelator systems or tricarbonyls
combined with tridentate coligands.
15,16 Conventionally the
design of a peptide molecule with spacers or linkers has the
objective to improve in vivo pharmacokinetics. Pegylation is
one of these strategies.
Rogers et al.
17 introduced a polyethylene glycol (PEG)
linking moiety into the biomolecular targeting vector to
prevent hindrance of the binding affinity of the BBN
7–
14NH2 motif with GRP receptors. Smith et al.,
18 reported the
flexibility of the lengh of the hydrocarbon spacer group.
b-Alanine (b-Ala) is a short amino acid spacer containing
three carbon atoms which is coupled to the active site of
BBN in order to achieve better in vitro and, particularly,
in vivo performance. In the current study b-Alanine and
polyethylene glycol were included in the molecular design.
The system combined morfolino and it’s complement
(cMORF) as well biotin-streptavidin.
The objective was investigation of the radiochemical and
biological profile of two BBN molecules administered by the
pretargeting protocol.
MATERIAL AND METHODS
Materials
The materials used in this study were:
– Biotinylated MORF and cMORF from Gene tools, OR,
USA
MORF - 5’-TCTTCTACTTCACAACTA-3’ biotin )- MW
6381
cMORF - 5’-TAGTTGTGAAGTAGAAGA-3’-Primary
amine – MW 6317
– Conjugated Biotinylated Bombesin Analog with two
different spacers from Peptide International, KY,USA
Biotin-b-Ala-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2
(MW 1237.52)
Biotin-dPEG-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2
(MW 1766.16)
– S-acetylmercaptoacetyltriglicine (S-MAG3) - synthesized
at University of Massachusetts, Worcester, MA, USA.
– MAG3-cMORF – conjugated at University of Massachu-
setts, Worcester, MA, USA
– Technetium-99m (
99mTc) was retrieved from an alumina-
based
99Mo/
99mTc generator, supplied by Radio-
pharmacy Center of the Institute of Energetic and
Nuclear Research (IPEN/CNEN)-Sa ˜o Paulo, Brazil
– MAG3-Ahx-BBN (Ahx – 6-aminohexanoic acid) –
piChem, Austria.
– Reagents and solutions (Trypsin, Glycine, Cell culture
solution RPMI with L-Glutamine) – Sigma-Aldrich and
Merck, Sa ˜o Paulo, Brazil
– Streptavidin (SA) – Pierce Protein Research Product –
Thermo Scientific, Rockford, IL, USA
– Human prostatic tumor cells PC-3, ATCC- Code CRL-
1435, USA.
– Animals – Male Swiss mice (20-30g) and Male Nude mice
(Balb/c) (15-20g) – Animal Facility of IPEN/CNEN-SP,
Brazil
N-hydroxysuccinimidyl S-acetylmercaptoacetyltriglycine
(NHS-MAG3) was synthesized and conjugation of MAG3-
cMORF was executed at University of Massachusetts, as
previously described.
19
Solution preparation
Solutions of different molecules were prepared in 0.5 M
NaCl/0.2M NH4OAc. Concentrations were: SA – 0.189 mM;
B-MORF - 0.3 mM; B-bAla-BBN - 0.2 mM; B-PEG-BBN -
0.2 mM and MAG3-cMORF - 0.053 mM.
Conjugation of biotin-morfolino (B-MORF) with
streptavidin (SA)
Biotin-MORF was added stepwise to streptavidin and
vortexed, at three different molar ratios (1:1, 1:2, 1:3).
Association of biotin-b-Ala-BBN and biotin-PEG-
BBN with SA
The conjugated peptides were associated with SA adopt-
ing the same ratios as for SA:B-BBN.
Radiolabeling of complementary morpholino
(MAG3-cMORF) with
99mTc
Complementary morpholino was labeled with
99mTc via
MAG3 procedure as previously described
20. Briefly 4 ml (100
- 200 mCi) of sodium pertechnetate was added to a solution
containing 10 mL de MAG3-cMORF (0.346 mg/ml in 0.25 M
ammonium acetate solution, pH 5.1), 4 ml sodium tartrate
dihydrated (50 mg/ml) pH 9.2 and 1.5 ml of SnCl2.2H2O
(4 m/ml) in 1 mg of sodium ascorbate/ ml of HCl 10 mM). The
mixture was heated for 20 min/100˚C.
Conjugation of the three molecules and
radiolabeling
a) SA + Biotin-MORF + Biotin-bAla-BBN + MAG3-
cMORF-
99mTc
b) SA + Biotin-MORF + Biotin-PEG-BBN + MAG3-
cMORF-
99mTc
Radiolabeled nano-peptides
Faintuch BL et al.
CLINICS 2011;66(2):327-336
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constant agitation in molar ratios of 1:1:3 and 1:1:2, followed
by radiolabeling.
Evaluation of conjugation and radiochemical
labeling by size-exclusion High Performance Liquid
Chromatography (HPLC)
All solutions were evaluated by size-exclusion HPLC to
define retention time and conjugation purity.
Superose-12 column (Amersham Pharmacia, NJ, USA)
was used with acetonitrile 20% in NaCl 1 M and NH4OAc
0.1 M eluant at a flow rate of 0.6 ml/min. The effluent was
monitored by in-line UV detector set at a wavelengh of
265 nm. Radioactivity was monitored by in-line NaI(Tl)
scintillation detector.
Cell Culture
PC3 human prostate adenocarcinoma cells expressing
bombesin receptor were cultured adherently in RPMI 1640
supplemented with 10% fetal calf serum at 37˚C. Cells were
detached from culture bottles by trypsinization (0.24%
trypsin/0.05% EDTA) and seeded into 12-well plates for
binding studies containing 10
6 cells/well.
In vitro binding experiments
Concentrations used in each well were:
cMORF -58 pM (380 pg); B-MORF – 196 pM (1.25 gg); B-
MORF/cMORF = 3.4 and B-bAla- BBN or B-PEG-BBN
362 pM (446.67 pg).
The medium was aspirated and the cells washed twice
with culture medium (RPMI). In well-plate 1 (in triplicate) it
was added: 100 ml of mixture (SA+B-MORF+B-Ala-BBN or
SA+B-MORF-PEG-BBN) + 900 ml culture medium. In well-
plate 2 (in triplicate) it was added: 100 ml of mixture (SA+B-
MORF+B-Ala or PEG-BBN) + 100 ml MAG3-Ahx-BBN
(1 mM- unlabeled ligand for specific binding) + 800 ml
culture medium.
The well-plates were incubated at 37˚C for three periods
of time (1, 3 and 5 hours). Afterwards the medium was
aspirated and the cells were washed twice with the culture
medium. Then it was added to all wells 100 ml
99mTc-MAG3-
cMORF + 900 ml culture medium. The plates were further
incubated for 10 minutes, then the supernatant was col-
lected. The wells were washed with cold PBS and the
material mixed together with the previous supernatant.
Glycine was added to the wells and then collected, and
finally wells were washed again with PBS, NaOH was
added, and the resulting fluid collected.
In vivo studies: cell inoculation in animals,
biodistribution and images
All animal studies were performed in accordance with the
Guidelines for the Care and Use of Research Animals
established by the Local Animal Welfare Committee.
The induction of tumor xenografts in Nude mice (age of 8
weeks) was done with PC-3 cells (5 6 10
6 cells/mouse)
subcutaneously injected on the upper right part of the back
of the animal. PC3 cells were allowed to grow in vivo for
about 10 days post inoculation, thus forming tumors with a
diameter of approximately one cm, adequate for experi-
ments with the radiotracer.
Animals were sacrificed at different times by cervical
dislocation. The main organs were removed and together
with samples of muscle and bone were weighed and
counted in a NaI (Tl) well counter (Cobra II, automatic c-
counter, Packard Instrument Company, USA), and biodis-
tribution data were calculated as percent of injected dose
per gram (% ID/g), using injected dose as standard.
Samples of blood were also taken along with stomach and
intestines which were emptied before the measurements.
Whole blood volume as well as total muscle mass were
assumed to be 7% and 40% of body weight respectively, for
the purpose of calculating %ID.
Biodistribution studies were conducted in three steps:
1. Evaluation of
99mTc-MAG3-cMORF in healthy Swiss
mice: It was conducted 1, 2 and 3 hours post injection.
2. Pretargeting system in healthy Swiss mice
50 ml of the mixture SA+B-MORF+B-bAla-BBN or SA+B-
MORF+PEG-BBN in the ratio (1:1:2) was injected in the tail
vein of the animals. Two hours after the scheduled times of
3, 5, 7, 15 and 24 hours the effector
99mTc-MAG3-cMORF
was administered by the same route. After two more hours
the animals were sacrificed and biodistribution performed
as described above (Scheme 1).
3. Pretargeting system in Nude mice bearing tumor cells
The same procedure of healthy animals was adopted but
restricted to two incubation times (7 and 15 hours). Effector
injection (
99mTc-MAG3-cMORF) and assessment of biodis-
tribution followed similar routines.
Imaging of tumor-bearing mice was done in gamma-
camera with horizontally-placed anesthetized animals
(Mediso Imaging System, Budapest, Hungary), employing
a low-energy high-resolution collimator. Images were
acquired with 2566256616 matrix size and 20% energy
window set at 140 keV for a period of 180 s.
Statistical Analysis
Tissue/organ distributions are presented as mean ¡ SD.
For differences between the two experimental groups
Student’s t-test was selected, to a significance level of 5%
(P,0.05).
RESULTS
HPLC analysis confirmed conjugation of morpholino and
it’s complementary molecule, as well as the bombesin
analogs which were combined with streptavidin.
Figure 1 shows that commercial MORF is not totally
biotinylated (only 60%) when using SA nanoparticles at
different ratios. However, for both bombesin analogs 100%
of the conjugated peptide was attached to biotin when
different ratios were used for conjugation with streptavidin,
showing a single peak (Fig. 2 and Fig. 3). Radiochemical
purity of
99mTc-MAG3-cMORF was 99.6% (Fig. 4), with Rt of
26.6 min. In order to compensate for free MORF, final
conditions were 1:1:2 and 1:1:3 SA/B-MORF/B-BBN. HPLC
analysis with radioactivity detection following addition of
99mTc-cMORF confirmed unimpaired hybridization (Fig 4).
Radioactivity recuperation was in the range of 73 to 82%.
Streptavidin possesses four biotin binding sites so Biotin-
MORF and Biotin-BBN competed for them. Due to this
competition, ratio between SA:B-MORF:B-BBN was evalu-
ated (Scheme 2).
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329Specific cell- binding (SB) was calculated by the difference
between values for well-plate 1 (total binding/T) and well-
plate 2 (non-specific binding/NSB). For the radiolabeled
bAla mixture (SA+B-MORF+B-bAla-BBN), total binding
was confirmed to be time dependent (Figure 5). The highest
accumulation (5.06¡1.98%) occurred with 1 hour of
incubation, decreasing on later times. Specific binding fell
to 1.05¡0.35%. This phenomenon did not hold true for the
pegylated molecule (Fig 6), the highest value being reached
at a later time (3 hours).
A superiority (87% more) in cell accumulation for B-b-
BBN as compared to B-PEG-BBN can be appreciated in
Figure 7.
Table 1 summarizes uptake in different organs and tissues
of
99mTc-MAG3-cMORF in healthy Swiss mice. Kidneys
came first, followed by intestine. Fast blood clearance was
documented, and an intermediate time point (2 hours) was
chosen for further studies.
Pretargeting biodistribution in healthy Swiss mice was
done at multiple times (Table 2 and 3) in order to define the
best schedule for the subsequent phase, namely pretargeting
of tumor-bearing Nude mice.
In healthy animals blood radioactivity was high for both
molecules decreasing only at 15 h (Tables 2 and 3, values in
%ID/ml). The numerical increase of blood uptake for both
mixtures b-Ala and PEG from 3 to 5 h (P=0.236 and
Scheme 1 - Pretargeting system.
Figure 1 - SE HPLC chromatogram profile with UV 265 detection (A) B-MORF; (B) SA; (C) SA/B-MORF (1:1); (D) SA/B-MORF (1:2); (E) SA/B-
MORF (1:3).
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330Figure 2 - UV Chromatogram profile (A) B-b-Ala-BBN; (B) SA: B-b-Ala-BBN (1:1); (C) SA: B-b-Ala-BBN (1:2); (D) SA: B-b-Ala-BBN (1:3).
Figure 3 - SE HPLC chromatogram of conjugation of Streptavidin with Biotin-PEG-BBN. (A) B- PEG-BBN; (B) SA:B-PEG-BBN (1:1); (C) SA:B-
PEG-BBN (1:2); (D) SA: B-PEG-BBN (1:3).
Figure 4 - Size exclusion HPLC radiochromatogram profile of: (A)
99mTc-MAG3-cMORF; (B) SA:B-MORF:B-bAla-BBN (1:1:3) + 99mTc-
MAG3-cMORF; (C) SA:B-MORF:B-bAla-BBN (1:1:2) +
99mTc-MAG3-cMORF.
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331P=0.288) as well from 5 to 7 h (P=0.404 and P= 0.695) was
not statistically confirmed. The only difference materiza-
lized for b-Ala from 3 to 7 h (P=0.028).
Renal excretion was remarkable for both conjugates,
without difference (P=0.69) between them. No difference
either could be demonstrated for pancreas uptake of b-Ala
and PEG by 7 h (P=0.33) and 15 h (P=0.45) (Tables 2 and
3). Lung as well intestinal distribution were also noteworthy
for both mixtures.
Uptake by most of organs and tissues was smaller in
tumor-bearing animals, (Figures 8, 9) when compared to
healthy ones.
Blood uptake of b-Ala decreased at 7 h (P=0.008) but not
of PEG, although a tendency could be perceived (P=0.08).
Kidney changes were not confirmed (P=0.15).
Highest tumor uptake for bAla was registered at 7 h
(2.58¡0.59 %ID/g) compared to just 0.97¡0.08 %ID/g for
PEG (P=0.013) (Figure 8). Measurements for 15 h were not
different from the former ones (Figure 9) (P=0.22 and
P=0.39) or between them (P=0.16).
Tumor/blood ratios are low in contrast with tumor/
muscle ratios, and both increase after 15 h (0.84 and 0.50 for
B-bAla-BBN and B-PEG-BBN respectively). Tumor/muscle
ratio for B-bAla-BBN at 7h was 5.95 and for B-PEG-BBN,
2.45, with a difference of 58.8% that remained rather stable
till 15 h.
Scintigraphic studies at 7 h unveiled a ROI of 3.9% for B-
bAla-BBN and of 1.47% for PEG (Figure 10). Images taken at
Scheme 2 - Design of competition between B-MORF and B-BBN
by SA sites and hybridization with
99mTc-MAG3-cMORF.
Figure 5 - Receptor binding to PC-3 cells of (SA+B-MORF+B-bAla-
BBN) with
99mTc-MAG3-cMORF.
Figure 6 - Receptor binding to PC-3 cells of (SA+B-MORF+B-PEG-
BBN) with
99mTc-MAG3-cMORF.
Figure 7 - Total binding to PC-3 cells of the mixtures plus
99mTc-
MAG3-cMORF.
Table 1 - Biodistribution of
99mTc-MAG3-cMORF in Swiss
mice.
Time (hours)
Organs/Tissues 1 2 3
Blood (%ID/ml) 0.41 ¡0.05 0.18 ¡ 0.02 0.09 ¡ 0.02
Heart 0.20 ¡ 0.03 0.10 ¡ 0.02 0.07 ¡ 0.02
Lung 0.53 ¡ 0.08 0.25 ¡ 0.03 0.17 ¡ 0.02
Kidneys 8.19 ¡ 2.43 4.64 ¡ 0.96 2.93 ¡ 0.06
Spleen 0.21 ¡ 0.04 0.12 ¡ 0.03 0.17 ¡ 0.01
Stomach 0.28 ¡ 0.08 0.38 ¡ 0.05 0.55 ¡ 0.13
Pancreas 0.30 ¡ 0.08 0.14 ¡ 0.02 0.12 ¡ 0.03
Liver 0.44 ¡ 0.06 0.52 ¡ 0.09 0.41 ¡ 0.04
Large Intestine 0.37 ¡ 0.03 0.33 ¡ 0.10 1.33 ¡ 0.38
Small Intestine 1.71 ¡ 0.41 0.65 ¡ 0.07 0.35 ¡ 0.12
Muscle 0.13 ¡ 0.01 0.18 ¡ 0.03 0.33 ¡ 0.03
Bone 0.35 ¡ 0.01 0.18 ¡ 0.03 0.23 ¡ 0.02
Data are expressed as %ID/g (n=6 mean values ¡ S.D)
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33215 h were associated with a reduced ROI (1.37% and 1.22 %
respectively).
DISCUSSION
The main focus for using pretargeting system instead of
conventional radiotherapeutic techniques is to improve
radioimaging and eventually radiotherapy.
21 Usually this
system is used for large biomolecules such as antibodies due
their high molecular weight and slow clearance. To the best
of our knowledge, this was the first attempt to combine
together a nanoparticle and the morpholino oligomer,
aiming at prostate cancer that exhibits receptors for
bombesin analogs.
Table 2 - Biodistribution of (SA+B-MORF+B-bAla -BBN) plus
99mTc-MAG3-cMORF by pretargeting system in healthy
animals.
Time (hours)
Organs/Tissues 3 5 7 15 24
Blood ( %ID/ml) 5.98 ¡ 1.26 7.96 ¡1.04 8.89 ¡ 0.52 1.70 ¡ 0.12 0.76 ¡ 0.34
Heart 2.23 ¡ 0.65 2.49 ¡0.16 2.91 ¡ 0.23 0.71 ¡ 0.17 0.28 ¡ 0.10
Lung 3.65 ¡1.31 3.94 ¡1.35 6.47 ¡ 1.46 1.12 ¡ 0.42 0.67 ¡ 0.25
Kidneys 12.66 ¡ 4.29 18.14¡5.6 17.63 ¡ 2.02 13.9 ¡ 9.18 7.51 ¡ 1.05
Spleen 1.44 ¡ 0.35 1.61 ¡ 0.2 2.37 ¡ 0.31 1.01 ¡ 0.56 0.43 ¡ 0.28
Stomach 2.35 ¡ 0.89 2.35 ¡ 0.3 2.91 ¡ 0.38 0.65 ¡ 0.08 0.47 ¡ 0.07
Pancreas 0.90 ¡ 0.24 1.36 ¡ 0.2 2.04 ¡ 0.47 1.20 ¡ 1.09 0.62 ¡ 0.52
Liver 1.97 ¡ 0.34 2.85 ¡ 0.3 3.36 ¡ 0.61 0.85 ¡ 0.15 0.74 ¡ 0.25
Large Intestine 2.26 ¡ 1.27 3.4 ¡ 1.91 3.41 ¡ 0.76 0.77 ¡ 0.12 0.77 ¡ 0.36
Small Intestine 2.7 ¡ 1.07 3.8 ¡ 1.04 7.69 ¡ 1.40 3.28 ¡ 0.96 2.54 ¡ 0.38
Muscle 1.01 ¡ 0.62 1.33 ¡ 0.7 0.92 ¡ 0.19 0.39 ¡ 0.08 0.19 ¡ 0.03
Bone 1.98 ¡ 0.50 2.16 ¡ 0.3 2.19 ¡ 0.06 1.67 ¡ 0.53 0.66 ¡ 0.08
Data are expressed as %ID/g (n=6 mean values ¡ S.D)
Table 3 - Biodistribution of (SA+B-MORF+B-PEG -BBN) plus
99mTc-MAG3-cMORF by pretargeting system in healthy
animals.
Time (hours)
Organs/Tissues 3 5 7 15 24
Blood ( %ID/ml) 7.15 ¡ 1.98 10.90 ¡ 2.98 9.05 ¡ 4.15 1.64 ¡ 0.07 1.22 ¡ 0.18
Heart 2.62 ¡ 0.36 2.83 ¡ 0.75 2.76 ¡ 1.19 0.63 ¡ 0.04 0.40 ¡ 0.10
Lung 4.63 ¡ 0.34 6.37 ¡ 3.08 5.01 ¡ 2.63 1.01 ¡ 0.20 0.79 ¡ 0.44
Kidneys 18.21¡ 3.69 17.76 ¡ 8.60 15.98 ¡ 8.1 9.06 ¡ 2.11 11.89 ¡ 2.82
Spleen 1.72 ¡ 0.18 2.38 ¡ 0.60 2.57 ¡ 0.94 0.47 ¡ 0.01 0.48 ¡ 0.12
Stomach 2.31 ¡ 0.73 3.18 ¡ 0.77 4.12 ¡ 1.93 0.80 ¡ 0.34 0.72 ¡ 0.15
Pancreas 1.36 ¡ 0.24 3.49 ¡ 0.22 3.97 ¡ 2.39 0.50 ¡ 0.02 0.48 ¡ 0.06
Liver 2.25 ¡ 0.07 3.09 ¡ 0.76 3.25 ¡ 1.97 0.62 ¡ 0.06 0.79 ¡ 0.12
Large Intestine 2.16 ¡ 0.32 6.17 ¡ 2.93 3.55 ¡ 1.26 0.74 ¡ 0.06 1.03 ¡ 0.13
Small Intestine 4.76 ¡ 1.11 8.02 ¡ 3.52 6.81 ¡ 3.67 2.47 ¡ 0.44 3.89 ¡ 1.03
Muscle 1.46 ¡ 0.61 1.03 ¡ 0.11 0.98 ¡ 0.46 0.26 ¡ 0.01 0.18 ¡ 0.02
Bone 3.01 ¡ 0.50 2.35 ¡ 1.01 2.55 ¡ 1.55 0.82 ¡ 0.06 0.69 ¡ 0.04
Data are expressed as %ID/g (n=6 mean values ¡ S.D)
Figure 8 - Biodistribution of (SA+B-MORF+B-bAla -BBN) and (SA+B-MORF+B-PEG-BBN) (7 h post injection) plus
99mTc-MAG3-cMORF (2 h
post injection) by pretargeting system in Nude mice bearing tumor cells.
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333Preliminary HPLC evidence was not favorable, as con-
jugation of the commercial biotin-morpholino complex was
incomplete upon addition of streptavidin. Only 60% was
biotinylated. Such finding demanded different molecular
ratios in order to achieved adequate results.
Previous studies have already addressed possible strate-
gies to optimize the pretargeting process, such as manip-
ulating the times for both administration of the pretargeting
agent and the radiolabeling effector.
21
Calculation of MORF and radiolabeled cMORF ratio is
another concern. The amount of cMORF must be low for
complete hybridization. In this investigation we considered
a ratio between 3 and 6 (more precisely 5.65), based on
reports of the literature.
12
Human prostate tumor PC-3 cells exhibit a large number
of GRP receptors on the cell surface. Reile and co-workers
22
and Montet et al,
23 have shown that there are as many as
44,000 bombesin receptor sites on PC-3 cells. Nevertheless,
high uptake is not granted despite such abundance. In
healthy animals the uptake in major organs was low to
moderate (,4% ID/g), with the exception of blood, lung,
kidneys and intestines, that took up higher proportions.
The increase in blood uptake from 3 to 7 h for conjugated
b-Ala was unexpected, but could be due to fluctuations in
glomerular filtration, as peptides and small proteins can be
reabsorbed in the proximal tubule.
24 The length and
composition of the spacer group in the molecule can
influence clearance of the radiopeptide by either the urinary
or hepatobilary system. Its role as known is to keep the
metal center and corresponding ligand framework some
distance away from the active site of the biomolecule, in
order to maintain reactivity in vivo.
9 In our study the few
difference between the two spacers, nominally b-Ala and
PEG, were limited to healthy animals.
High kidney accumulation could be attributed to the
large number (six) of cytosines in the base sequence.
25
Unfortunately documentation of radioactivity in urine and
bladder was lacking because given the long observation
period, animals weren’t anesthesized.
No influence by different spacers was observed on renal
and intestinal uptake. Usually when hydrocarbon chain
length increases, renal excretion decreases, while clearance
via the hepatobiliary pathway is enhanced.
26
Inhibition of renal uptake can be achieved by a combina-
tion of lysine and arginine
27 or using a cytosine-free
cMORF.
25 Such maneuvers could be advantageous for
prostate imaging, as they tend to attenuate overlapping
activity of the urinary bladder.
The pancreas is another interesting goal for BBN.
Schuhmacher et al.
28 report that the GRP-receptor density
in mice is in the following order: pancreas.tumor.intes-
tine. In our study, pancreatic uptake in healthy animals
reached the highest value at 7 h (3.64 ¡ 1.89 %ID/g for PEG
and 2.04 ¡ 0.47 %ID/g for b Ala). Values were less
encouraging in tumor-bearing rodents, but further optimi-
zation should be carried out.
The 7 h investigation time was based on pancreatic
uptake in healthy animals at 7 h, however by that time
blood concentration was already falling. By 15 h tumor/
blood ratio was low as well, suggesting that injections
earlier than 7 h should be the priority for the future.
Figure 9 - Biodistribution of (SA+B-MORF+B-bAla -BBN) and (SA+B-MORF+B-PEG-BBN) (15h post injection) plus
99mTc-MAG3-cMORF (2 h
post injection) by pretargeting system in Nude mice bearing tumor cells.
Figure 10 – Scintigraphic images - (A) B-MORF-B-bAla-BBN +
99mTc-cMORF (A)(ROI= 3.9%); (B) B-MORF-B-PEG-BBN +
99mTc-
cMORF (ROI= 1.47%).
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334La Bella et al,
29 labeled BBN with
999mTc-carbonyl, with
low uptake in PC-3 tumor-bearing mice (0.89 ¡ 0.27 %ID/g)
but high uptake into the pancreas (7.11 ¡ 3.93 %ID/g),
confirming that discrepancies may exist, thus requiring
additional testing.
The highest tumor accumulation, observed for B-bAla-
BBN in cell culture was confirmed by highest uptake in
tumor-bearing animals for this same spacer.
As a rule, Nude mice displayed lower uptake in main
organs and tissues than Swiss controls. Maina et al.
30 states
that BBN peptides may have different structure-function
relationships in different species.
In our previous experience with a standard technique
9
findings were roughly comparable to those here achieved.
With different isotopes, spacers and chelating agents, even
higher uptake than with pretargeting has been occasionally
announced.
15,18,26,29,31 Nevertheless species differences are
not rare,
30 and in the case of human cancer irregular
responses are quite common,
31 with false positives and
negatives. Consequently, interpretation of numerical results
does not always indicate the true clinical impact of the
method. Pretargeting procedures may improve tumor-to
nontumor (T/NT) ratio therefore studies with this modality
are important and should be continued.
14,21,25
Metastases were not part of this protocol, however
preliminary observations with
99mTc-bombesin suggest
good diagnostic ability in humans.
31,32 Indeed nanoparticles
seem to exhibit highly desirable features for lymph node
imaging. Though currently emphasized agents are lipo-
somes, quantum dots, dendrimers and magnetic nanopar-
ticles, bombesin analogues administered by the pretargeting
technique might prove an option as well.
33
CONCLUSIONS
Streptavidin nanoparticles intended for MORF/cMORF
pretargeting may be prepared with peptides such as bom-
besin as pretargeting agents.
Competition between B-MORF and B-BBN for the 4 sites
of Streptavidin was observed. The best combination of the
mixture was achieved using the ratio 1:1:2 for SA/B-MORF/
B-BBN respectively.
Encouraging tumor uptake was documented at both 7 h
and 15 h. The study demonstrates that the pretargeting
approach with a peptide is a viable concept, and deserves
further evaluation with appropriate modifications in the
sequence of MORF, including less cytosine, different
pretargeting intervals, and also metastasis models.
ACKNOWLEDGMENTS:
This investigation was supported by Fundacao de Amparo a Pesquisa do
Estado de Sao Paulo (Grant 2007/57616-2). Part of this study was
conducted at the University of Massachusetts/UMass, Worcester, MA,
USA , and appreciation is expressed for the guidance and support of all
professors and staff of the Department of Radiology, UMass. Natanael
Gomes da Silva was responsible for technical imaging, Angelica Garbuio
and Roselaine Campos Targino for cell culture and Maria Neide Ferreira
Mascarenhas for animal facilities.
REFERENCES
1. Trottier G, Lawrentschuk N, Fleshner NE. Prevention strategies in
prostate cancer. Curr Oncol. 2010;17 Suppl 2:S4-S10.
2. Chopra A. [111In]-DOTA-Aminohexanoyl-[D-Phe6,Leu-NHCH2CH2
CH313, desMet14] BBN[6-14] [111In]Bomproamide]. Molecular
Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda
(MD): National Center for Biotechnology Information (US); 2004-2010
(2010 May 20).
3. Chanda N, Kattumuri V, Shuka R, Zambre A, Katti K, Upendran A, et al.
Bombesin functionalized gold nanoparticles show in vitro and in vivo
cancer receptor specificity. Proc Natl Acad Sci U S A. 2010; 107:8760-5,
doi: 10.1073/pnas.1002143107.
4. Liu Z, Yan Y, Liu S, Wang F, Chen X.
18F,
64Cu, and
68Ga Labeled RGD-
Bombesin Heterodimeric Peptides for PET Imaging of Breast Cancer.
Bioconjugate Chem. 2009;20:1016–25, doi: 10.1021/bc9000245.
5. Anastasi A, Espamer V, Bucci M. Isolation and structure of bombesin
and alytesin, 2 analogous active peptides from the skin of the European
amphibians Bombina and Alytes. Experientia. 1971;27:166-7, doi: 10.
1007/BF02145873.
6. McDonald TJ, Jornvall H, Nilsson G, Vagne M, Ghatei M, Bloom SR, et al.
Characterization of a gastrin releasing peptide from porcine non-antral
gastric tissue. Biochem Biophys Res Commun. 1979; 90:227-33, doi: 10.
1016/0006-291X(79)91614-0.
7. Flores DG, Lenz G, Roesler R, Schwartsmann G. Gastrin-releasing
peptide receptor signaling in cancer. Cancer Therapy. 2009;7: 332-46.
8. Parry JJ, Andrews R, Rogers BE. MicroPET imaging of breast cancer
using radiolabeled bombesin analogs targeting the gastrin-releasing
peptide receptor. Breast Cancer Res Treat. 2007;101: 175-83, doi: 10.1007/
s10549-006-9287-8.
9. Faintuch BL, Teodoro R, Duatti A, Muramoto E, Faintuch S, Smith CJ.
Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical
studies Nucl Med Biol. 2008;35:401–11.
10. Van de Wiele C, Dumont F, Diercks RA, Peers SH, Thornback JR, Slegers
G, et al. Biodistribution and dosimetry of 99mTc-RP527, a gastrin-
releasing peptide (GRP) agonist for the visualization of GRP receptor-
expressing malignancies. J Nucl Med. 2001;42: 1722-7.
11. Mang’era KO, Liu G, Yi W, Zhang Y, Liu N, Gupta S, et al. Initial
investigations of 99mTc-labeled morpholinos for radiopharmaceutical
applications. Eur J Nucl Med. 2001;28:1682-9.
12. Liu G, Liu C, Zhang S, He J, Liu N, Gupta S, et al. Investigations of
99mTc morpholino pretargeting in mice. Nucl Med Commun.
2003;24:697-705, doi: 10.1097/00006231-200306000-00013.
13. Wang Y, Liu X, Nakamura K, Chen L, Rusckowski M, Hnatowich DJ. In
vivo delivery of antisense MORF oligomer by MORF/carrier streptavidin
nanoparticles. Cancer Biother Radiopharm. 2009;24: 573-8, doi: 10.1089/
cbr.2009.0624.
14. Liu G, He J, Dou S, Gupta S, Rusckowski M, Hnatowich DJ. Further
investigations of morpholino pretargeting in mice--establishing quanti-
tative relations in tumor. Eur J Nucl Med Mol Imaging. 2005; 32:1115-23,
doi: 10.1007/s00259-005-1853-5.
15. Smith CJ, Sieckman GL, Owen NK, Hayes DL, Mazuru DG, Kannan R,
et al. Radiochemical investigations of gastrin-releasing peptide receptor-
specific[(99m)Tc(X)(CO)3-Dpr-Ser-Ser-Ser-Gln-Trp-Ala-Val-Gly-His-
Leu-Met-(NH2)] in PC-3, tumor-bearing, rodent models: Syntheses,
radiolabeling, and in vitro/in vivo studies where Dpr = 2,3-diaminopro-
pionic acid and X = H2O or P(CH2OH)3. Cancer Res. 2003;63:4082-8.
16. Lane SR, Veerendra B, Rold TL, Sieckman GL, Hoffman TJ, Jurisson SS,
et al.
99mTc(CO)3-DTMA bombesin conjugates having high affinity for
the GRP receptor. Nucl Med Biol. 2008;35:263-72, doi: 10.1016/j.
nucmedbio.2007.11.007.
17. Rogers BE, Manna DD, Safavy A. In vitro and in ivo evaluatin of a 64Cu-
labeled polyethythylene glycol-bombesin conjugate. Cancer Biother
Radiopharm. 2004;19:25-34, doi: 10.1089/108497804773391649.
18. Smith CJ, Gali H, Sieckman GL, Higginbotham C, Volkert WA, Hoffman
TJ. Radiochemical Investigations of 99mTc2N3S-X-BBN[7214]NH2: An
in Vitro/in Vivo Structure2Activity Relationship Study Where X = 0-,
3-, 5-, 8-, and 11-Carbon Tethering Moieties. Bioconjugate Chem. 2003;14:
93–102, doi: 10.1021/bc020034r.
19. Wang Y, Liu X, Hnatowich DJ. An improved synthesis of NHS-MAG3
for conjugation and radiolabeling of biomolecules with (99m)Tc at room
temperature. Nat Protoc. 2007;2:972-8, doi: 10.1038/nprot.2007.144.
20. Liu G, Mang’era K, Liu N, Gupta S, Rusckowski M, Hnatowich DJ.
Tumor pretargeting in mice using (99m)Tc-labeled morpholino, a DNA
analog. J Nucl Med. 2002;43:384-91.
21. Liu G, Dou S, He J, Liu X, Rusckowski M, Hnatowich DJ.-Predicting the
biodistribution of radiolabeled cMORF effector in MORF-pretargeted
mice. Eur J Nucl Med Mol Imaging. 2007;34:237-46, doi: 10.1007/s00259-
006-0222-3.
22. Reile H, Armatis PE, Schally AV. Characterization of high-affinity
receptors for bombesin/gastrin releasing peptide on the human prostate
cancer cell lines PC-3 and DU-145:internalization of receptor bound 125I-
(Tyr4) bombesin by tumor cells. Prostate. 1994;25:29-38, doi: 10.1002/
pros.2990250105.
23. Montet X, Yuan H, Weissleder R, Josephson L. Enzyme-based visualiza-
tion of receptor-ligand binding in tissues. Lab Invest. 2006;86:517-25, doi:
10.1038/labinvest.3700404.
24. Akizawa H, Uehara T, Arano Y. Renal uptake and metabolism of
radiopharmaceuticals derived from peptides and proteins. Adv Drug
Deliv Rev. 2008;60:1319-28, doi: 10.1016/j.addr.2008.04.005.
CLINICS 2011;66(2):327-336 Radiolabeled nano-peptides
Faintuch BL et al.
33525. Liu G, He J, Dou S, Gupta S, Vanderheyden JL, Rusckowski M, et al.
Pretargeting in tumored mice with radiolabeled morpholino oligomer
showing low kidney uptake. Eur J Nucl Med Mol Imaging. 2004;31:417-
24, doi: 10.1007/s00259-003-1393-9.
26. SmithCJ,SieckmanGL,OwenNK,HayesDL,MazuruDG,KannanR,etal.
Radiochemical investigations of [99mTc(H2O)(CO)3-Dpr-(X)-Bombesin(7-
14)NH2],anewfamilyofGRP-receptortargetingradiopharmaceuticals.In:
Technetium, Rhenium and Other Metals in Chemistry and Nuclear
Medicine – Marino Nicolini Uderico Mazzi, 2002:339-44.
27. Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and
effective inhibition of renal uptake of radiolabelled octreotide by a
combination of lysine and arginine. Eur J Nucl Med Mol Imaging.
2003;30:9-15, doi: 10.1007/s00259-002-0982-3.
28. Schuhmacher J,Zhang H, DollJ,Ma ¨ckeHR, MatysR,HauserH, et al.GRP
receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice
with a 68Ga-labeled bombesin (6-14) analog. J. Nucl Med. 2005;46:691-9.
29. La Bella R, Garayoa EG, Bahler M, Blauenstein P, Schibli R, Conrath P,
et al. A 99mTc(I)-postlabeled high affinity bombesin analogue as a
potential tumor imaging agent. Bioconjugate Chem. 2002;13:599-604, doi:
10.1021/bc015571a.
30. Maina T, Nock BA, Zhang H, Nikolopoulou A, Waser B, Reudi JC.
Species differences of bombesin analog interactions with GRP-Rdefine
the choice of animal models in the development of GRP-R-targeting
drugs. J Nucl Med. 2005;46:823-30.
31. De Vincentis G, Remediani S, Varvarigou AD, Di Santo G, Iori F,
Laurenti C, et al. Role of
99mTc-bombesin scan in diagnosis and staging of
prostate cancer. Cancer Biother Radiopharm. 2004; 19:81-4, doi: 10.1089/
108497804773391711.
32. Scopinaro F, De Vincentis G, Varvarigou AD, Laurenti C, Iori F,
Remediani S, et al. 99mTc-bombesin detects prostate cancer and invasion
of pelvic lymph nodes. Eur J Nucl Med Mol Imaging. 2003;30:1378-82,
doi: 10.1007/s00259-003-1261-7.
33. Jain R, Dandekar P, Patravale V. Diagnostic nanocarriers for sentinel
lymph node imaging. J Control Release. 2009;138:90-102, doi: 10.1016/j.
jconrel.2009.05.010.
Radiolabeled nano-peptides
Faintuch BL et al.
CLINICS 2011;66(2):327-336
336